Aetna, a CVS Health company, announced that 87 percent of its Medicare Advantage (MA) members are in 2024 Medicare Advantage Prescription Drug (MAPD) plans that are rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS). This represents a significant achievement, given the considerably more stringent CMS measurement criteria this year. “We are committed to delivering outstanding experiences and driving improved health outcomes for our Medicare Advantage members,” said CVS Health President and CEO Karen S. Lynch. “Our strong 2024 Star Ratings for Aetna are a result of focused execution and seamless collaboration across our entire company. We remain unwavering in our efforts to drive continuous improvement to support our members now and well into the future.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVS:
- CVS pulled PR suggesting Stars setback rectified, says Deutsche Bank
- CVS Health says ‘do not have knowledge of final 2024 Star ratings’
- Agilon Health price target lowered to $20 from $21 at Evercore ISI
- CVS Health price target lowered to $80 from $93 at Bernstein
- Walgreens (NYSE:WBA) Staff Could Stage a Walkout Today